Cibus (CBUS) Stock Price, News & Analysis

Company Overview

Cibus, Inc. is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships. Cibus collaborates with seed companies, growers and research institutions to advance commercial trait pipelines for crops such as canola, pennycress and potato. By applying its RTDS technology, Cibus aims to shorten development timelines and reduce regulatory complexity compared with traditional genetic modification approaches.

Headquartered in San Diego, California, Cibus serves customers and partners across North America and Europe. The company maintains research and development facilities dedicated to molecular biology, genomics and field-based trait evaluation. Through strategic alliances, Cibus has expanded its global footprint, offering tailored solutions to support sustainable agriculture and meet evolving market needs.

Cibus is led by an experienced management team with deep expertise in agricultural biotechnology, genomics and crop sciences. The leadership group guides the company’s efforts to bring innovative, non-transgenic trait solutions to market, positioning Cibus at the forefront of the next generation of precision breeding technologies.

Key Stats

• Today's Range: $1.59 to $1.63
• 50-Day Range: $1.39 to $2.39
• 52-Week Range: $1.09 to $4.19
• Volume: 85,885 shs
• Average Volume: 116,700 shs
• Market Capitalization: $121.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Cibus Stock Analysis - MarketRank™

Cibus scored higher than 32% of companies evaluated by MarketBeat, and ranked 744th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cibus has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Cibus has a consensus price target of $9.00, representing about 466.0% upside from its current price of $1.59.

Amount of Analyst Coverage

Cibus has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cibus are expected to grow in the coming year, from ($1.13) to ($1.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cibus is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cibus is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cibus has a P/B Ratio of 3.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.32% of the float of Cibus has been sold short.

Short Interest Ratio / Days to Cover

Cibus has a short interest ratio ("days to cover") of 19.14, which indicates bearish sentiment.

Change versus previous month

Short interest in Cibus has recently decreased by 6.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cibus does not currently pay a dividend.

Dividend Growth

Cibus does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Cibus this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for CBUS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cibus insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.91% of the stock of Cibus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

33.81% of the stock of Cibus is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/09/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CBUS
• Previous Symbol: NASDAQ:CBUS
• CIK: 1705843
• Web: www.cibus.com
• Phone: (858) 450-0008
• Fax: N/A
• Employees: 48
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Cibus: $9.00
• High Price Target: $15.00
• Low Price Target: $3.00
• Potential Upside/Downside: +466.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.08 million
• Net Margins: -2,258.89%
• Pretax Margin: -2,291.35%
• Return on Equity: -287.03%
• Return on Assets: -27.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.62
• Quick Ratio: 1.62

Sales & Book Value

• Annual Sales: $3.64 million
• Price / Sales: 33.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.40 per share
• Price / Book: 3.98

Miscellaneous

• Outstanding Shares: 76,430,000
• Free Float: 53,569,000
• Market Cap: $121.52 million
• Optionable: Optionable
• Beta: 1.59